4:10 PM ET
10-Q
Financial Results
Apimeds Pharmaceuticals US Q3 2026 Results: Turns Profitable, Net Income $33.6M
Apimeds Pharmaceuticals US, Inc. reported a net loss of $21.6 million for the nine months ended September 30, 2026, compared to a $4.8 million loss in the prior year. The company transitioned its operations, recording its first software development revenue of $2.48 million while managing a significant digital asset portfolio valued at $142.4 million.
- Key figure
- Net income $33.6M